The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan.

GUANGZHOU, China, March 23, 2026 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today ...

Ono's $2.4 billion acquisition of Deciphera, Novartis' new radioligand therapy deal with PeptiDream, and WuXi Biologics' withdrawal from BIO 2024 made our news this ...

This is an ETF that invests in 28 Japanese companies that earn more than half of their revenue from "Bio & MedTech," such as ...

DORADO, PR / ACCESS Newswire / September 14, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.

GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets ...

Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has synthesized glucagon-like peptide 1 receptor (GLP-1R), glucagon receptor (GCGR) and gastric inhibitory polypeptide receptor (GIPR) agonists that are ...

Samjong KPMG and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association jointly held the "2026 Pharma-Bio ...

Community members on Wednesday had the chance to sit down with workers in the bio-pharma and life sciences sector.

Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has discovered new prodrugs of glucagon-like peptide 1 (GLP-1) polypeptides acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be ...